NTD | Jotup

Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

Retrieved on:

måndag, april 8, 2024

Astrotech, SDVOSB, Conference, Transport, ETD, Intelligence, Knowledge, NTD, Aviation, European Civil Aviation Conference, Small business, GSA, Mass spectrometry, TSA, ASTC, TRACER

AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect’s TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA’s thorough evaluation determined that 1st Detect’s pricing is fair and reasonable, that 1st Detect had the requisite capabilities, organizational structure, customer satisfaction and performance history, and that the offered products and services are compliant with applicable laws and regulations.

Key Points:

IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world.
The TRACER 1000 maintains the accuracy of much larger mass spectrometers even though it is only the size of a desktop printer.
The Astrotech Mass Spectrometer Technology™ drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry.
1st Detect has engaged with SRI Group LLC, a distinguished GSA provider led by retired Deputy Administrator of the Transportation Security Administration (TSA) John Halinski.

Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

Retrieved on:

tisdag, april 2, 2024

The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ (“AMS Technology”).

Key Points:

The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ (“AMS Technology”).
Currently, the Company’s Tracer 1000 ETD is now found in multiple locations in 14 countries throughout the world.
“We are extremely excited to share our user-friendly mass spectrometer the TRACER 1000, which is powered by our AMS Technology, with leading industry experts and security industry professionals at the ISC West conference.
The TRACER 1000 is the first mass spectrometry-based ETD to have received European Civil Aviation Conference (“ECAC”) certification for both checkpoint and cargo security.

Astrotech Introduces the “Gold Standard” of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

Retrieved on:

måndag, mars 25, 2024

Astrotech, Conference, Heroin, Cocaine, ETD, Law enforcement, NTD, Prison, European Civil Aviation Conference, Airport, Mass spectrometry, ASTC, TRACER, Fentanyl, Drug

The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.

Key Points:

The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.
Currently, the Company’s Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution.
The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

torsdag, mars 21, 2024

Well, Research, Administration, Development, ASH, EPP, MF, Patient, NTD, Trial of the century, Ruxolitinib, IRON, Anemia, Porphyria, JAK

“The past year has been truly remarkable for Disc and marks another important chapter in our company’s story.

Key Points:

“The past year has been truly remarkable for Disc and marks another important chapter in our company’s story.
During 2023, we provided the first evidence of the therapeutic potential of our programs, with positive read-outs in patients for both bitopertin and DISC-0974.
The increase was primarily due to the completion of a registered direct offering in February 2023 and a publicly marketed follow-on offering in June 2023.
The increase was primarily due to higher operating costs in the current period to support the continued advancement of our pipeline.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on:

tisdag, april 2, 2024

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points:

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Global H3N2 infection Drug Pipeline Landscape Report 2024: Insights on 15+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on:

tisdag, februari 27, 2024

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.

Key Points:

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.
A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines.
The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development.
The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e.

Bybit to Host Exclusive VIP Gathering Events in Taiwan Alongside ETH Taipei

Retrieved on:

fredag, mars 8, 2024

VIP, Very important person, Trust, Blockchain, NTD, Cryptocurrency

DUBAI, UAE, March 8, 2024 /PRNewswire/ -- Bybit , one of the world's top three crypto exchanges by volume, today announced an exclusive VIP gathering event in Taipei on March 23, coinciding with ETH Taipei, the largest blockchain event in Taiwan.

Key Points:

DUBAI, UAE, March 8, 2024 /PRNewswire/ -- Bybit , one of the world's top three crypto exchanges by volume, today announced an exclusive VIP gathering event in Taipei on March 23, coinciding with ETH Taipei, the largest blockchain event in Taiwan.
This exclusive event offers Bybit VIP clients a unique opportunity to:
Network with fellow industry leaders and Bybit representatives.
Additionally, the first 88 new VIPs will receive the following:
Ben Zhou, Co-founder and CEO of Bybit stated, "We are thrilled to host this exclusive gathering for our valued VIP clients during ETH Taipei week.
Bybit, through this exclusive event, demonstrates its dedication to supporting the local blockchain community and fostering meaningful connections with its VIP clients.

Bybit to Host Exclusive VIP Gathering Events in Taiwan Alongside ETH Taipei

Retrieved on:

fredag, mars 8, 2024

VIP, Very important person, Trust, Blockchain, NTD, Cryptocurrency

DUBAI, UAE, March 8, 2024 /PRNewswire/ -- Bybit , one of the world's top three crypto exchanges by volume, today announced an exclusive VIP gathering event in Taipei on March 23, coinciding with ETH Taipei, the largest blockchain event in Taiwan.

Key Points:

DUBAI, UAE, March 8, 2024 /PRNewswire/ -- Bybit , one of the world's top three crypto exchanges by volume, today announced an exclusive VIP gathering event in Taipei on March 23, coinciding with ETH Taipei, the largest blockchain event in Taiwan.
This exclusive event offers Bybit VIP clients a unique opportunity to:
Network with fellow industry leaders and Bybit representatives.
Additionally, the first 88 new VIPs will receive the following:
Ben Zhou, Co-founder and CEO of Bybit stated, "We are thrilled to host this exclusive gathering for our valued VIP clients during ETH Taipei week.
Bybit, through this exclusive event, demonstrates its dedication to supporting the local blockchain community and fostering meaningful connections with its VIP clients.

The macroeconomic effects of global supply chain reorientation

Retrieved on:

lördag, februari 10, 2024

Bank, Control, Quarterly Journal of Economics, Literature, Deutsche Bundesbank, Reconstruction, COVID-19, Monetary policy, Medical classification, Aggregate, Interest, Hail, Motion, Organization, WT, Policy, Smith, Elasticity, American Economic Review, Information, CHiPs, Journal of Economic Perspectives, Reproduction, Tagliapietra, Culture, Journal of International Economics, Section 3, European Commission, Communication, B16, Shock, NTM, European Chips Act, SSC, PHT, B17, Classification, Common, Tradability, Bank of Italy, Congressional Research Service, NT, Central bank, Private, Exercise, NIU, Labour, PDF, Website, European Parliament, Terrorism, Employment, B10, SUBST, Agricultural economics, F62, RTK, Bank of England, European Central Bank, Calibration, Agriculture, Foreign policy, Semiconductor, International Monetary Fund, Research Papers in Economics, Outline, Council, Openness, Bias, Economic system, European Council, Public policy, Deutsch, Statistics, GDP, Real, American Economic Journal, Table, Journal, YT, EAGLE, Household, Grossman, Science, Conference, Journal of Comparative Economics, Horse, SSRN, TC, Consumption, REA, F13, Section 2, University, Section 5, Legislation, Money, NTD, Central Bank of Ireland, Language, Capital, University of Limerick, Intermediate, CBI, Caselli, Macroeconomics, Crowding, Technical report, B14, Tax, Civil service commission, Growth, Commission, UNCTAD, Optimism, Politics, PIM, PX, Work, Social science, JEL, Government, Automation, HTT, Quarterly Journal, Canadian International Council, ECB, XT, METRO, ELAS, Credit, Bolt, Research, European Communities, American Journal, ArXiv, Unilateralism, Lerner, Motivation, International, C6, Committee, Security (finance)

We analyse the macroeconomic

Key Points:

We analyse the macroeconomic
effects of supply chain reorientation through localisation policies, using a global dynamic
general equilibrium model.
While arguments about comparative advantage, the potential forgone benefits of international specialisation and industry- and product-specific disruptions are familiar, there is less
analysis on the macroeconomic effects of supply chain changes resulting from localisation policies.
The large sensitivity of the global economy to the recent supply chain shocks suggests that
the international trade reconfiguration implied by localisation policies could also have sizable
impacts on key macroeconomic variables such as output, employment and inflation.
Thus, localisation focuses on the
goods in our model most closely related to global supply chains.
Retaliation also attenuates any positive effects from
reshoring on output and implies a reduction in the volume of overall international trade.
This finding calls for limiting the scope of reshoring, such as by focusing on vital goods that are
most susceptible to supply chain disruptions.
Either that, or the economic costs are considered a worthwhile trade-off for an increase
in security of supply, for example.
While arguments about comparative advantage, the potential forgone benefits of international specialisation and industry- and product-specific disruptions are familiar, there is less
analysis on the macroeconomic effects of supply chain changes resulting from localisation policies.
Recent supply chain shocks have had large effects, with disruptions in 2021 estimated
to have reduced euro area GDP by around two percent and doubled the rate of manufacturing producer inflation (Celasun et al., 2022).
To analyse this issue, we simulate a (partial) reshoring of production back to Europe in
a global dynamic general equilibrium framework.
Thus,
localisation focuses on the goods in our model most closely related to global supply chains.3 We
model reshoring through a direct change to the export goods? production-function parameters.
Since reshoring
effectively shortens the supply chain, the sum of markups along the chain falls.
This means that imports that are at the end of the supply chain (i.e.
In particular, our work relates to papers examining the potential for countries to reduce
their exposure to global supply chains.
(2021) demonstrate that reduced reliance on foreign inputs does not mitigate pandemicinduced contractions in labour supply.
(2021) find no evidence of a relationship
between global value chain integration and macroeconomic volatility.
This dynamic, along with factors such as natural disasters, climate-change
induced volatility and terrorism mean that supply chain disruptions could be a new normal
(Grossman et al., 2021).
Our work contributes to the literature providing dynamic general equilibrium analyses of
protectionist policies, in particular those using global macroeconomic models to quantify trade
policy changes.
(2008) analyse the effect of a rise in protectionism in response
to rising global trade imbalances.
Linde? and Pescatori (2019) find that although the macroeconomic costs of a
trade war are substantial, a fully symmetric retaliation is the best response.
(2020) consider a rich input-output structure and demonstrate that closer integration amplifies
the adverse effects of protectionist trade policies.
Several recent studies have also examined the economic effects of a global trade fragmentation.
First, we modify a dynamic general
equilibrium model of the global economy in order to analyse the transmission of localisation
policies.
This allows for a comprehensive treatment of cross-border macroeconomic interdependences and spillovers between the different regions.
4
There is, however, substantial cross-country heterogeneity in terms of impact, with small open economies
(SOEs) reliant on global supply chains more affected.
ECB Working Paper Series No 2903
7

Second, we are able to assess both long-run effects and the transition dynamics of localisation
policies.
Our model contains a detailed monetary block and captures inflation dynamics, which is a key
concern for supply chain reorientation.
Overall, our paper contains a careful analysis of the key aspects of the localisation debate,
including effects of localisation on domestic competition and efficiency.
Section 2 provides a brief overview of the model, the modifications to examine
global supply chain reorientation, some key details on the calibration and a brief discussion of
the nature of our exercise.
(2020) for discussions of the relative strengths and weaknesses of
trade and macroeconomic models in assessing large economic shocks.
2.1
Supply chain reorientation

Our analysis focuses on imported inputs used to produce goods for export, as the introduction
of localisation policies is in response to recent disruptions to global supply chains.
Since reshoring
effectively shortens the supply chain, the sum of markups along the chain falls.
Further to
these effects, engagement with global firms provides an opportunity for knowledge spillovers to
local firms (Criscuolo et al., 2017).
This finding calls for limiting the scope of reshoring, such as by focusing on vital goods that are
most susceptible to supply chain disruptions.
(B12)
Adjusting the share of local inputs in export goods, of course, affects prices and quantities all
along the supply chain.

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

Retrieved on:

onsdag, januari 3, 2024

Agios Pharmaceuticals, Partnership, Thalassemia, BID, American University of Beirut, Disease, Mortality, Host, Head, Hematology, American University, Patient, AGIO, NTD, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism and pioneering therapies for rare diseases, today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.

Key Points:

Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
“The results of the Phase 3 ENERGIZE study underscore the potential of mitapivat to be a meaningful treatment option for adults with non-transfusion dependent alpha- or beta-thalassemia.
All subgroup analyses favored the mitapivat treatment arm compared to placebo,” said Sarah Gheuens, M.D., Ph.D., chief medical officer and head of R&D at Agios.
ET to review the ENERGIZE Phase 3 data and next steps for the Phase 3 ENERGIZE-T study.